Table 1.

Changes in King’s Health Questionnaire Scores After Therapy

Domain	Solifenacin 5 mg*	Solifenacin 10 mg*	Tolterodine ER 4 mg†	Tolterodine 2 mg‡	Oxybutynin 2.5/5 mg‡	Darifenacin 7.5/15 mg‡	Fesoterodine 4 mg†	Fesoterodine 8 mg§	Oxybutynin Transdermal‡
General health	−4.3	−4.0	−1.9	−0.45	0.58	0.15	−2.9	−2.6	−1.2
Incontinence impact	−24.7	−27.3	−22.7	−10.38	−8.62	−19.42	−7.8	−9.6	−13.5
Role limitations	−20.6	−22.7	−21.5	−11.44	−9.07	−21.30	−18.5	−21.4	−13.3
Physical limitations	−17.7	−20.3	−18.8	−8.23	−8.01	−17.79	−17.2	−19.6	−11.7
Social limitation	−11.3	−11.7	−13.2	−6.16	−6.77	−10.62	−11.6	−13.8	−6.7
Personal relationships	−8.7	−9.3	−10.0	−2.78	−5.0	−5.41	−7.8	−9.6	−6
Emotions	−16.0	−17.7	−14.2	−4.57	−6.51	−11.75	−12.4	−15.3	−8.8
Sleep/energy	−13.8	−14.4	−12.7	−5.98	−6.15	−8.10	−10.7	−12.3	−11.2
Severity(coping) measure	−10.5	−13.2	−12.4	−6.16	−5.48	−8.77	−11.3	−13.7	−8.6

ER, extended release.

^*P < .001 compared with placebo.

^†P < .01 compared with placebo.

^‡P < .001 compared with baseline.

^§P < .05 compared with placebo.